The company has pivoted from medical device market focus to aerospace, transportation, and industrial sectors, now delivering results through this strategic shift. With a $14.2M backlog that began monetizing in 2025, the company is targeting aerospace platforms (UAVs, helicopters) and securing commercial industrial orders, reflecting growing market adoption of its dual-use visual sensing and AI analytics technologies.
Cyborg Score Rationale
The company completed its Nasdaq uplisting in February 2025 with $23.7M in gross proceeds, strengthening cash position. While 9-month 2025 gross margins were 27% with $14.4M operating expenses leading to a $12.8M net loss, the monetizing backlog and strategic sector shift provide growth visibility.
Top Insights
European flight tests on AW139 helicopters underway with Heron TP UAV deliveries and a 200-unit commercial industrial purchase order announced
Revenue mix now reflects aerospace, transportation and industrial sectors, validating long-term commercial potential of core technology
Analyst rating is "Strong Buy" with 12-month price target of $10
Key risk: backlog cancellation or delay could impact revenue timing and sustainability of operating spend relative to $29.8M cash balance